The aim of this study was to demonstrate that UNISTRAIN® PRRS administered by the intradermal route (ID) with a suitable device was as effective as when administered with a conventional intramuscular injection (using needle and syringe) in piglets after a heterologous challenge at 24 weeks post-vaccination.